AgeX Therapeutics, Inc., based in Alameda, California, focuses on developing and commercializing innovative therapeutics for aging and degenerative diseases using telomerase-expressing stem cells. Its key candidates, AGEX-BAT1 and AGEX-VASC1, target metabolic disorders and vascular diseases, respectively.
Gregory Bailey bought 6,400 shares of SER on 15 August at $6.65 per share, worth a total of $43K. They now own 33,006 SER shares, or a 24% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
